| 27.06.2022 |
Bulletin on Drug Safety - Current Issue 2/2022 Published |
| 24.06.2022 |
First Gene Therapy for Haemophilia A Receives a Recommendation for Authorisation |
| 24.06.2022 |
The EMA Committee for Medicinal Products for Human Use Recommends the Authorisation of Novavax’s COVID-19 Vaccine Nuvaxovid for Adolescents Aged 12 to 17 Years |
| 23.06.2022 |
An Informational Visit – BMG State Secretary Dr Antje Draheim at the Paul-Ehrlich-Institut |
| 21.06.2022 |
Rolling Reviews Have Started for Adapted COVID-19 mRNA Vaccines from BioNTech (Comirnaty) and Moderna (Spikevax) |
| 20.06.2022 |
The President of the Paul-Ehrlich-Institut, Professor Klaus Cichutek, becomes a "real Langener" at the Ebbelwoi Festival |
| 19.05.2022 |
Application Submitted for Conditional Marketing Authorisation of the COVID-19 Vaccine VLA2001 from Valneva |
| 17.05.2022 |
Vaccine Production: Strengthening Quality Infrastructure in African Countries |
| 02.05.2022 |
ZEPAI to Manage Supply of Pandemic Vaccines in Germany |
| 25.04.2022 |
Suspected Cases of Adverse Reactions and Vaccination Complications after Vaccination with Comirnaty in Children aged 5 to 11 Years from Germany |
| 21.04.2022 |
COVID-19 Vaccine Comirnaty – Shelf Life Extended to 12 Months |
| 31.03.2022 |
Application Submitted for Conditional Marketing Authorisation of the Protein-based COVID-19 Vaccine Candidate Vidprevtyn |
| 30.03.2022 |
Bulletin on Drug Safety - Current Issue 1/2022 Published |
| 29.03.2022 |
Paul-Ehrlich-Institut Calls Again upon Doctors and Pharmacists to Order Flu Vaccines |
| 29.03.2022 |
Rolling Review for COVID-19 Booster Vaccine HIPRA Has Begun |
| 25.03.2022 |
CHMP Recommends Authorisation of the SARS-CoV-2 Neutralising Monoclonal Antibody Combination Evusheld (Tixagevimab and Cilgavimab) for COVID-19 Therapy |
| 25.03.2022 |
Authorisation Granted for the Monoclonal Antibody Combination Evusheld (Tixagevimab and Cilgavimab) for COVID-19 Prevention |
| 14.03.2022 |
Monoclonal Antibody Combination Evusheld for the Prevention of COVID-19 Available in Germany |
| 04.03.2022 |
EU Commission Follows CHMP Recommendation: Marketing Authorisation Extension of Moderna's COVID-19 Vaccine Spikevax for Use in Children Aged 6 Years and up |
| 03.03.2022 |
For the Progress of Biomedicines: Paul-Ehrlich-Institut in Discussion with the German Pharmaceutical Industry Association (BPI) |
| 01.03.2022 |
EU Commission Follows CHMP Recommendation: Booster Vaccination with COVID-19 Vaccine Comirnaty for Children and Adolescents 12 years and up |
| 22.02.2022 |
Nuvaxovid (Novavax) – Protein-based COVID-19 Vaccine Available on a Limited Basis in Germany |
| 21.02.2022 |
COVID-19 Pandemic – Focus on Vaccines |
| 10.02.2022 |
European Evaluation Process for Booster Vaccination with COVID-19 Vaccine Comirnaty in 12 to 15-Year-Olds |
| 03.02.2022 |
Improving the Availability of Veterinary Medicinal Products and Preventing Antibiotic Resistance – New Legal Framework |
| 02.02.2022 |
Comirnaty COVID-19 mRNA Vaccine – Shelf Life Extended for Additional Formulations |
| 01.02.2022 |
Use of Monoclonal Antibodies against COVID-19 – Xevudy (Sotrovimab) Available in Germany |
| 28.01.2022 |
Professor Reinhold Schmidt, Chairman of the Scientific Advisory Board of the Paul-Ehrlich-Institut, has passed away |
| 14.01.2022 |
COVID-19 Vaccine Spikevax – Shelf Life Extended |
| 14.01.2022 |
Reduced Efficacy of Ronapreve (Casirivimab/Imdevimab) against Omicron Variant |
| 10.01.2022 |
In Conversation with Professor Klaus Cichutek – Why Vaccines Do Not Have Long-Term Effects |
| 06.01.2022 |
Flu Vaccination – Now is the Time |
| 05.01.2022 |
Safety, Immunogenicity and Interchangeability of Biosimilars |
